Evidence map›Paper›PMID 41233473›Full record

ArticleScientific reports2025

Isolation and characterization of biofilm-disrupting proteus phage Premi.

Guadalupe Valencia-Toxqui, Shobana Sugumar, Jolene Ramsey

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. A One Health Perspective onMicroorganisms · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Guadalupe Valencia-Toxqui *Department of Biology, Center for Phage Technology, Texas A&M University, College Station, TX, USA.
Shobana Sugumar *Department of Genetic Engineering, Faculty of Engineering and Technology, School of Bioengineering, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, Kanchipuram, Chennai, Tamil Nadu, India.
Jolene RamseyDepartment of Biology, Center for Phage Technology, Texas A&M University, College Station, TX, USA. jolenerr@tamu.edu.

Funding

Bacteriophage strategies to lyse bacterial cellsR35GM155289 · NIGMS · TEXAS A&M UNIVERSITY · PI Jolene Ramsey · 2024 to 2026
$1.1M
National Institute of General Medical Sciences of the National Institutes of Health R35GM155289NIGMS NIH HHS R35 GM155289
6 · The paper itself

Abstract

Proteus mirabilis is a biofilm-forming, multidrug-resistant bacterium and one of the most common causes of catheter-associated urinary tract infections (CAUTIs). Phage therapy is an alternative method that can be used to address the problem of multidrug-resistance. In this study, we report isolation and characterization of virulent phage Premi. The phage exhibits lytic activity against 4 out of 30 clinical isolates of P. mirabilis tested and is stable when exposed to pH values between 3 and 11. Phage Premi demonstrated significant anti-biofilm activity against P. mirabilis, reducing 24-hour established biofilms by 59-68%. In the 42-kb Premi genome, functions were assigned for the 50 predicted protein-coding genes including those involved in DNA replication, DNA modification, and lysis. Structural proteins were verified using mass spectrometry of purified virions. A comparison of its genomic features and phylogenetic analysis revealed that phage Premi is a podophage member of the order Caudoviricetes sharing 96% nucleotide similarity with Proteus phage PM 85 and has a T7-like phage genomic organization. Our study shows that Premi effectively inhibits P. mirabilis biofilms and could be a promising antimicrobial agent for treating drug-resistant P. mirabilis infection.

Indexed as

BacteriophagesBiofilmsProteus mirabilisGenome, ViralHumansPhage TherapyPhylogenyProteus InfectionsCAUTIMultidrug-resistancePhagePodophageProteusUTI

Identifiers

PMID41233473
PMCPMC12615708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.